| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bronchopulmonary Dysplasia | 18 | 2021 | 34 | 5.870 |
Why?
|
| Infant, Premature, Diseases | 12 | 2021 | 85 | 4.380 |
Why?
|
| Infant, Premature | 20 | 2022 | 284 | 4.160 |
Why?
|
| Intensive Care Units, Neonatal | 13 | 2021 | 113 | 3.150 |
Why?
|
| Lung | 17 | 2021 | 849 | 3.100 |
Why?
|
| Hyperoxia | 8 | 2020 | 27 | 2.450 |
Why?
|
| Infant, Newborn | 40 | 2022 | 2453 | 2.270 |
Why?
|
| Steroids | 5 | 2021 | 84 | 1.970 |
Why?
|
| Gestational Age | 21 | 2021 | 389 | 1.910 |
Why?
|
| Pulmonary Surfactants | 7 | 2021 | 41 | 1.860 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 7 | 2021 | 46 | 1.780 |
Why?
|
| Patient Discharge | 5 | 2021 | 294 | 1.710 |
Why?
|
| Infant | 18 | 2022 | 2891 | 1.410 |
Why?
|
| Oxygen | 9 | 2021 | 386 | 1.290 |
Why?
|
| Animals, Newborn | 19 | 2020 | 396 | 1.230 |
Why?
|
| Receptors, Atrial Natriuretic Factor | 3 | 2021 | 11 | 1.220 |
Why?
|
| Infant, Newborn, Diseases | 3 | 2022 | 91 | 1.220 |
Why?
|
| Respiratory Tract Diseases | 3 | 2021 | 43 | 1.160 |
Why?
|
| Sheep | 11 | 2021 | 128 | 1.100 |
Why?
|
| Enterocolitis, Necrotizing | 3 | 2022 | 37 | 1.090 |
Why?
|
| Alveolar Epithelial Cells | 2 | 2021 | 28 | 1.010 |
Why?
|
| Infant, Very Low Birth Weight | 6 | 2022 | 69 | 0.880 |
Why?
|
| Enteral Nutrition | 3 | 2022 | 157 | 0.860 |
Why?
|
| Pulmonary Medicine | 1 | 2021 | 31 | 0.800 |
Why?
|
| Transient Tachypnea of the Newborn | 1 | 2020 | 1 | 0.770 |
Why?
|
| Hypertension, Pulmonary | 4 | 2018 | 232 | 0.730 |
Why?
|
| Evidence-Based Medicine | 1 | 2022 | 438 | 0.720 |
Why?
|
| Humans | 53 | 2022 | 68525 | 0.710 |
Why?
|
| Respiration, Artificial | 10 | 2017 | 190 | 0.690 |
Why?
|
| Natriuretic Peptide, C-Type | 2 | 2017 | 5 | 0.690 |
Why?
|
| Cerebral Palsy | 1 | 2018 | 24 | 0.670 |
Why?
|
| Disabled Children | 1 | 2018 | 16 | 0.670 |
Why?
|
| Bronchodilator Agents | 1 | 2019 | 43 | 0.670 |
Why?
|
| Oxygen Inhalation Therapy | 4 | 2016 | 32 | 0.660 |
Why?
|
| NFI Transcription Factors | 1 | 2017 | 6 | 0.630 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2017 | 109 | 0.590 |
Why?
|
| Nitric Oxide | 8 | 2021 | 382 | 0.590 |
Why?
|
| Career Choice | 1 | 2017 | 98 | 0.570 |
Why?
|
| Aorta | 1 | 2018 | 316 | 0.570 |
Why?
|
| Medicaid | 1 | 2018 | 301 | 0.560 |
Why?
|
| Gastrostomy | 3 | 2021 | 110 | 0.550 |
Why?
|
| Animals | 28 | 2022 | 20877 | 0.540 |
Why?
|
| Atrial Natriuretic Factor | 2 | 2021 | 54 | 0.530 |
Why?
|
| Pneumonia | 1 | 2016 | 110 | 0.520 |
Why?
|
| Risk Assessment | 3 | 2019 | 2004 | 0.500 |
Why?
|
| Pregnancy | 13 | 2021 | 2331 | 0.490 |
Why?
|
| Growth Substances | 2 | 2005 | 77 | 0.490 |
Why?
|
| Female | 35 | 2021 | 38015 | 0.480 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2021 | 234 | 0.470 |
Why?
|
| Pediatrics | 1 | 2017 | 341 | 0.470 |
Why?
|
| Antioxidants | 2 | 2020 | 304 | 0.470 |
Why?
|
| Biomedical Research | 1 | 2017 | 310 | 0.470 |
Why?
|
| Hospitalization | 2 | 2019 | 977 | 0.460 |
Why?
|
| Premature Birth | 4 | 2021 | 148 | 0.410 |
Why?
|
| Inflammation Mediators | 2 | 2015 | 244 | 0.400 |
Why?
|
| Peroxidase | 2 | 2010 | 40 | 0.380 |
Why?
|
| Dexamethasone | 3 | 2021 | 150 | 0.380 |
Why?
|
| Oxidative Stress | 2 | 2017 | 718 | 0.380 |
Why?
|
| Respiratory Mucosa | 2 | 2008 | 52 | 0.370 |
Why?
|
| Prospective Studies | 6 | 2020 | 3702 | 0.370 |
Why?
|
| Superoxide Dismutase | 2 | 2010 | 149 | 0.370 |
Why?
|
| Terbutaline | 2 | 2021 | 23 | 0.360 |
Why?
|
| Disease Models, Animal | 5 | 2020 | 2550 | 0.360 |
Why?
|
| Cytokines | 2 | 2017 | 866 | 0.350 |
Why?
|
| Infant, Low Birth Weight | 3 | 2019 | 84 | 0.340 |
Why?
|
| Lung Diseases | 2 | 2008 | 175 | 0.340 |
Why?
|
| Hyperventilation | 1 | 2008 | 6 | 0.340 |
Why?
|
| Guanylate Cyclase | 2 | 2008 | 25 | 0.340 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2009 | 64 | 0.340 |
Why?
|
| Administration, Inhalation | 6 | 2019 | 187 | 0.340 |
Why?
|
| Hydrocortisone | 2 | 2021 | 291 | 0.330 |
Why?
|
| Male | 27 | 2022 | 37281 | 0.330 |
Why?
|
| Mice | 6 | 2021 | 8472 | 0.320 |
Why?
|
| Child, Preschool | 4 | 2019 | 3185 | 0.320 |
Why?
|
| Workload | 1 | 2009 | 103 | 0.320 |
Why?
|
| Disease Transmission, Infectious | 1 | 2008 | 25 | 0.320 |
Why?
|
| Candida albicans | 1 | 2008 | 38 | 0.320 |
Why?
|
| Candidiasis | 1 | 2008 | 39 | 0.320 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2008 | 35 | 0.320 |
Why?
|
| Transforming Growth Factor alpha | 3 | 2004 | 30 | 0.310 |
Why?
|
| Cross Infection | 2 | 2008 | 195 | 0.300 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2008 | 186 | 0.290 |
Why?
|
| Retrospective Studies | 5 | 2021 | 7264 | 0.290 |
Why?
|
| United States | 6 | 2019 | 7335 | 0.280 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2021 | 265 | 0.280 |
Why?
|
| Intermittent Positive-Pressure Breathing | 1 | 2005 | 1 | 0.270 |
Why?
|
| Intermittent Positive-Pressure Ventilation | 1 | 2005 | 2 | 0.270 |
Why?
|
| Biomarkers | 5 | 2021 | 1593 | 0.270 |
Why?
|
| Continuous Positive Airway Pressure | 3 | 2020 | 33 | 0.270 |
Why?
|
| Adenoviridae Infections | 1 | 2005 | 6 | 0.270 |
Why?
|
| Lymphocytes | 2 | 2016 | 228 | 0.270 |
Why?
|
| Survival Rate | 4 | 2019 | 1055 | 0.260 |
Why?
|
| Fetus | 3 | 2006 | 157 | 0.260 |
Why?
|
| Child | 4 | 2021 | 6400 | 0.260 |
Why?
|
| Treatment Outcome | 5 | 2019 | 7028 | 0.260 |
Why?
|
| Disease Outbreaks | 1 | 2005 | 83 | 0.250 |
Why?
|
| Pulmonary Artery | 4 | 2009 | 323 | 0.250 |
Why?
|
| Breast Feeding | 2 | 2017 | 159 | 0.240 |
Why?
|
| Defecation | 1 | 2003 | 8 | 0.240 |
Why?
|
| Urination | 1 | 2003 | 19 | 0.240 |
Why?
|
| Infant Formula | 1 | 2003 | 24 | 0.240 |
Why?
|
| Biological Products | 2 | 2020 | 78 | 0.240 |
Why?
|
| Infant, Extremely Premature | 2 | 2021 | 18 | 0.230 |
Why?
|
| Internship and Residency | 1 | 2009 | 596 | 0.230 |
Why?
|
| RNA, Messenger | 3 | 2021 | 1663 | 0.220 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2016 | 219 | 0.220 |
Why?
|
| Cysteine | 1 | 2022 | 112 | 0.220 |
Why?
|
| Morphine | 1 | 2022 | 76 | 0.220 |
Why?
|
| Cell Differentiation | 2 | 2018 | 1034 | 0.210 |
Why?
|
| Rabbits | 5 | 2014 | 509 | 0.210 |
Why?
|
| Betamethasone | 1 | 2021 | 24 | 0.210 |
Why?
|
| Body Fluids | 1 | 2021 | 41 | 0.210 |
Why?
|
| Vasoconstriction | 5 | 2009 | 81 | 0.210 |
Why?
|
| Transcription, Genetic | 1 | 2004 | 562 | 0.210 |
Why?
|
| Cyclic GMP | 2 | 2014 | 99 | 0.200 |
Why?
|
| Perinatology | 1 | 2021 | 8 | 0.200 |
Why?
|
| Glucocorticoids | 2 | 2021 | 222 | 0.200 |
Why?
|
| Lactic Acid | 1 | 2021 | 86 | 0.200 |
Why?
|
| Editorial Policies | 1 | 2021 | 32 | 0.200 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2021 | 66 | 0.190 |
Why?
|
| Metalloporphyrins | 1 | 2020 | 25 | 0.190 |
Why?
|
| Methacholine Chloride | 2 | 2020 | 20 | 0.190 |
Why?
|
| Pulmonary Fibrosis | 1 | 2002 | 157 | 0.190 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 1174 | 0.190 |
Why?
|
| Gastrin-Releasing Peptide | 1 | 2020 | 3 | 0.190 |
Why?
|
| Resuscitation | 4 | 2009 | 77 | 0.180 |
Why?
|
| Pulmonary Circulation | 3 | 2010 | 79 | 0.180 |
Why?
|
| Energy Metabolism | 1 | 2021 | 222 | 0.180 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 3256 | 0.180 |
Why?
|
| RNA, Small Interfering | 1 | 2021 | 434 | 0.180 |
Why?
|
| Constriction, Pathologic | 1 | 2020 | 236 | 0.180 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2018 | 29 | 0.180 |
Why?
|
| Birth Weight | 2 | 2018 | 186 | 0.180 |
Why?
|
| Transcriptome | 1 | 2021 | 164 | 0.170 |
Why?
|
| New York | 1 | 2019 | 223 | 0.170 |
Why?
|
| Methylprednisolone | 1 | 2019 | 99 | 0.170 |
Why?
|
| Prednisone | 1 | 2019 | 104 | 0.170 |
Why?
|
| Milrinone | 2 | 2010 | 12 | 0.170 |
Why?
|
| Phosphodiesterase Inhibitors | 2 | 2010 | 28 | 0.170 |
Why?
|
| Adult | 6 | 2021 | 21375 | 0.170 |
Why?
|
| Diuretics | 1 | 2019 | 96 | 0.170 |
Why?
|
| Morbidity | 1 | 2019 | 130 | 0.170 |
Why?
|
| Epoprostenol | 2 | 2010 | 71 | 0.170 |
Why?
|
| Cohort Studies | 3 | 2020 | 2356 | 0.170 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 848 | 0.160 |
Why?
|
| Signal Transduction | 1 | 2008 | 2688 | 0.160 |
Why?
|
| Ultrasonography | 1 | 2020 | 453 | 0.160 |
Why?
|
| Meconium | 1 | 2017 | 2 | 0.160 |
Why?
|
| Endothelial Cells | 1 | 2021 | 384 | 0.160 |
Why?
|
| Fetal Blood | 2 | 2015 | 131 | 0.160 |
Why?
|
| Hemizygote | 1 | 2017 | 1 | 0.160 |
Why?
|
| Chemokine CXCL2 | 1 | 2017 | 13 | 0.160 |
Why?
|
| Hemodynamics | 3 | 2010 | 705 | 0.160 |
Why?
|
| Recurrence | 1 | 2020 | 948 | 0.150 |
Why?
|
| Annual Reports as Topic | 1 | 2017 | 12 | 0.150 |
Why?
|
| Feces | 1 | 2017 | 88 | 0.150 |
Why?
|
| Cell Line | 1 | 2021 | 1752 | 0.150 |
Why?
|
| Pertussis Toxin | 1 | 2017 | 72 | 0.150 |
Why?
|
| Models, Biological | 1 | 2021 | 981 | 0.150 |
Why?
|
| Infant, Extremely Low Birth Weight | 1 | 2017 | 5 | 0.150 |
Why?
|
| Respiratory Tract Infections | 1 | 2018 | 91 | 0.150 |
Why?
|
| Nutritional Status | 1 | 2017 | 112 | 0.150 |
Why?
|
| Intensive Care, Neonatal | 1 | 2016 | 38 | 0.140 |
Why?
|
| Endothelium-Dependent Relaxing Factors | 2 | 2006 | 2 | 0.140 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 1998 | 154 | 0.140 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2018 | 226 | 0.140 |
Why?
|
| History, 21st Century | 1 | 2016 | 126 | 0.140 |
Why?
|
| Bronchi | 2 | 2006 | 59 | 0.140 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2017 | 121 | 0.140 |
Why?
|
| Muscle, Smooth | 1 | 2016 | 117 | 0.140 |
Why?
|
| Interleukin-12 | 1 | 2016 | 75 | 0.140 |
Why?
|
| Chemokine CCL2 | 1 | 2016 | 101 | 0.140 |
Why?
|
| History, 20th Century | 1 | 2016 | 248 | 0.140 |
Why?
|
| Fibroblast Growth Factor 7 | 2 | 2007 | 6 | 0.130 |
Why?
|
| Dandy-Walker Syndrome | 1 | 1995 | 3 | 0.130 |
Why?
|
| Pulmonary Surfactant-Associated Protein B | 2 | 2012 | 8 | 0.130 |
Why?
|
| Chromosome Deletion | 1 | 1995 | 41 | 0.130 |
Why?
|
| Inflammation | 2 | 2014 | 1030 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 1995 | 54 | 0.130 |
Why?
|
| Chorioamnionitis | 1 | 2015 | 40 | 0.130 |
Why?
|
| Sex Factors | 1 | 2018 | 1265 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 2790 | 0.130 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2015 | 126 | 0.120 |
Why?
|
| Abnormalities, Multiple | 1 | 1995 | 109 | 0.120 |
Why?
|
| Vasodilator Agents | 3 | 2010 | 138 | 0.120 |
Why?
|
| Prevalence | 1 | 2018 | 1609 | 0.120 |
Why?
|
| Term Birth | 1 | 2013 | 12 | 0.120 |
Why?
|
| Norepinephrine | 4 | 2009 | 276 | 0.120 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 498 | 0.120 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 1851 | 0.120 |
Why?
|
| Risk Factors | 3 | 2019 | 5719 | 0.120 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2015 | 199 | 0.120 |
Why?
|
| Phenotype | 1 | 2016 | 946 | 0.120 |
Why?
|
| Interleukin-6 | 1 | 2015 | 330 | 0.120 |
Why?
|
| Vascular Resistance | 3 | 2010 | 179 | 0.110 |
Why?
|
| Pregnancy Outcome | 1 | 2013 | 157 | 0.110 |
Why?
|
| Time Factors | 5 | 2018 | 4655 | 0.110 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 2264 | 0.110 |
Why?
|
| Endothelium, Vascular | 2 | 2021 | 371 | 0.100 |
Why?
|
| South Carolina | 1 | 2018 | 2750 | 0.100 |
Why?
|
| Gene Expression Regulation, Developmental | 3 | 2015 | 328 | 0.100 |
Why?
|
| Down-Regulation | 3 | 2009 | 447 | 0.100 |
Why?
|
| Influenza Vaccines | 1 | 2011 | 56 | 0.100 |
Why?
|
| Influenza, Human | 1 | 2011 | 79 | 0.100 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 2798 | 0.090 |
Why?
|
| Antibodies, Viral | 1 | 2011 | 110 | 0.090 |
Why?
|
| Vasodilation | 3 | 2021 | 85 | 0.090 |
Why?
|
| Heart Defects, Congenital | 1 | 1995 | 596 | 0.090 |
Why?
|
| Pulmonary Alveoli | 3 | 2009 | 62 | 0.090 |
Why?
|
| Pulmonary Ventilation | 2 | 2006 | 28 | 0.090 |
Why?
|
| Logistic Models | 3 | 2020 | 1419 | 0.090 |
Why?
|
| Hospitals, Teaching | 1 | 2009 | 65 | 0.090 |
Why?
|
| Accreditation | 1 | 2009 | 72 | 0.080 |
Why?
|
| Chronic Disease | 2 | 2018 | 1329 | 0.080 |
Why?
|
| Oxidoreductases | 1 | 2009 | 117 | 0.080 |
Why?
|
| Respiratory Function Tests | 1 | 2008 | 123 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2017 | 1745 | 0.080 |
Why?
|
| Substance-Related Disorders | 1 | 1998 | 1241 | 0.080 |
Why?
|
| DNA Fingerprinting | 1 | 2008 | 11 | 0.080 |
Why?
|
| Cyclic GMP-Dependent Protein Kinases | 1 | 2008 | 10 | 0.080 |
Why?
|
| Molecular Epidemiology | 1 | 2008 | 16 | 0.080 |
Why?
|
| Thionucleotides | 1 | 2008 | 21 | 0.080 |
Why?
|
| Phosphatidylcholines | 1 | 2008 | 38 | 0.080 |
Why?
|
| DNA, Fungal | 1 | 2008 | 20 | 0.080 |
Why?
|
| Radiography, Thoracic | 1 | 2008 | 99 | 0.080 |
Why?
|
| Blotting, Northern | 1 | 2008 | 189 | 0.080 |
Why?
|
| Peptide Hydrolases | 1 | 2008 | 82 | 0.080 |
Why?
|
| Protease Inhibitors | 1 | 2008 | 76 | 0.080 |
Why?
|
| Quality Assurance, Health Care | 1 | 2009 | 177 | 0.080 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2007 | 22 | 0.080 |
Why?
|
| Umbilical Veins | 1 | 2007 | 54 | 0.080 |
Why?
|
| Platelet-Derived Growth Factor | 2 | 2007 | 45 | 0.080 |
Why?
|
| Carrier State | 1 | 2008 | 39 | 0.080 |
Why?
|
| Pulmonary Surfactant-Associated Protein A | 1 | 2007 | 16 | 0.080 |
Why?
|
| Catheters, Indwelling | 1 | 2007 | 72 | 0.080 |
Why?
|
| Continuity of Patient Care | 1 | 2009 | 170 | 0.080 |
Why?
|
| Cells, Cultured | 2 | 2015 | 2673 | 0.080 |
Why?
|
| Tropoelastin | 1 | 2007 | 2 | 0.080 |
Why?
|
| Phosphates | 1 | 2007 | 72 | 0.080 |
Why?
|
| Pleural Effusion | 1 | 2007 | 74 | 0.080 |
Why?
|
| Intubation, Intratracheal | 2 | 2020 | 99 | 0.070 |
Why?
|
| Neutrophils | 1 | 2008 | 204 | 0.070 |
Why?
|
| Physician-Patient Relations | 1 | 2009 | 261 | 0.070 |
Why?
|
| Lymphocyte Activation | 2 | 2021 | 397 | 0.070 |
Why?
|
| Aerosols | 2 | 2020 | 42 | 0.070 |
Why?
|
| Mothers | 1 | 2008 | 172 | 0.070 |
Why?
|
| Consensus Development Conferences, NIH as Topic | 1 | 2006 | 5 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 710 | 0.070 |
Why?
|
| Antihypertensive Agents | 1 | 2010 | 497 | 0.070 |
Why?
|
| Epithelium | 1 | 2006 | 172 | 0.070 |
Why?
|
| Apgar Score | 1 | 2005 | 22 | 0.070 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2005 | 24 | 0.070 |
Why?
|
| Reactive Oxygen Species | 1 | 2008 | 499 | 0.070 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2005 | 2 | 0.070 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2002 | 117 | 0.070 |
Why?
|
| Rats | 3 | 2022 | 5300 | 0.070 |
Why?
|
| Muscle Contraction | 1 | 2006 | 210 | 0.070 |
Why?
|
| Receptors, Growth Factor | 1 | 2005 | 6 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 331 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2005 | 216 | 0.060 |
Why?
|
| Cell Division | 2 | 2002 | 541 | 0.060 |
Why?
|
| Incidence | 1 | 2008 | 1582 | 0.060 |
Why?
|
| Morphogenesis | 1 | 2005 | 158 | 0.060 |
Why?
|
| Macrophages | 1 | 2008 | 647 | 0.060 |
Why?
|
| Clinical Competence | 1 | 2009 | 657 | 0.060 |
Why?
|
| Epidermal Growth Factor | 1 | 2004 | 95 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2005 | 714 | 0.060 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2004 | 110 | 0.060 |
Why?
|
| Esters | 1 | 2022 | 22 | 0.060 |
Why?
|
| Enzyme Inhibitors | 2 | 2021 | 659 | 0.050 |
Why?
|
| ErbB Receptors | 1 | 2004 | 239 | 0.050 |
Why?
|
| Sodium Chloride | 1 | 2002 | 136 | 0.050 |
Why?
|
| Fibroblast Growth Factors | 1 | 2002 | 51 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2022 | 334 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2021 | 1548 | 0.050 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2021 | 67 | 0.050 |
Why?
|
| A549 Cells | 1 | 2021 | 50 | 0.050 |
Why?
|
| Random Allocation | 3 | 2007 | 442 | 0.050 |
Why?
|
| Analgesics | 1 | 2022 | 118 | 0.050 |
Why?
|
| Consensus | 1 | 2022 | 211 | 0.050 |
Why?
|
| Plethysmography, Whole Body | 1 | 2020 | 1 | 0.050 |
Why?
|
| Bronchoconstrictor Agents | 1 | 2020 | 6 | 0.050 |
Why?
|
| Arteries | 1 | 2021 | 108 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2022 | 2083 | 0.050 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2020 | 34 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2003 | 1046 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2021 | 308 | 0.050 |
Why?
|
| Respiration Disorders | 1 | 2020 | 20 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2020 | 411 | 0.040 |
Why?
|
| Proteins | 1 | 2002 | 473 | 0.040 |
Why?
|
| Maternal-Fetal Exchange | 1 | 1998 | 57 | 0.040 |
Why?
|
| Infant Health | 1 | 2017 | 5 | 0.040 |
Why?
|
| Interleukin-8 | 1 | 2018 | 71 | 0.040 |
Why?
|
| Neonatal Screening | 1 | 1998 | 43 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2002 | 1692 | 0.040 |
Why?
|
| Potassium Chloride | 2 | 2009 | 45 | 0.040 |
Why?
|
| Neonatal Abstinence Syndrome | 1 | 1998 | 27 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2022 | 413 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2017 | 85 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2017 | 150 | 0.040 |
Why?
|
| Developmental Disabilities | 1 | 1998 | 119 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 208 | 0.040 |
Why?
|
| Sheep, Domestic | 2 | 2007 | 5 | 0.040 |
Why?
|
| Ficoll | 1 | 2016 | 1 | 0.040 |
Why?
|
| Centrifugation, Density Gradient | 1 | 2016 | 36 | 0.040 |
Why?
|
| Miniaturization | 1 | 2016 | 21 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2017 | 242 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2016 | 53 | 0.040 |
Why?
|
| In Vitro Techniques | 2 | 2009 | 765 | 0.040 |
Why?
|
| Age Factors | 2 | 2017 | 1860 | 0.040 |
Why?
|
| Linear Models | 1 | 2018 | 521 | 0.040 |
Why?
|
| Bacteria | 1 | 2017 | 193 | 0.040 |
Why?
|
| Disease Management | 1 | 2018 | 248 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 68 | 0.030 |
Why?
|
| Cell Separation | 1 | 2016 | 132 | 0.030 |
Why?
|
| Vasoconstrictor Agents | 2 | 2007 | 107 | 0.030 |
Why?
|
| Prognosis | 1 | 2021 | 2093 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 567 | 0.030 |
Why?
|
| Macrophages, Alveolar | 1 | 1995 | 34 | 0.030 |
Why?
|
| Chromosome Banding | 1 | 1995 | 24 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 489 | 0.030 |
Why?
|
| Aging | 2 | 2006 | 911 | 0.030 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2015 | 32 | 0.030 |
Why?
|
| Immunologic Memory | 1 | 2015 | 75 | 0.030 |
Why?
|
| CD4 Antigens | 1 | 2015 | 42 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 1995 | 164 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2015 | 94 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1054 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2016 | 652 | 0.030 |
Why?
|
| Homeostasis | 1 | 2015 | 291 | 0.030 |
Why?
|
| Blood Pressure | 2 | 2010 | 1447 | 0.030 |
Why?
|
| Creatinine | 1 | 2014 | 243 | 0.030 |
Why?
|
| Delivery, Obstetric | 1 | 2013 | 58 | 0.030 |
Why?
|
| Cesarean Section | 1 | 2013 | 101 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 1737 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2014 | 737 | 0.030 |
Why?
|
| Vaccines, Inactivated | 1 | 2011 | 3 | 0.030 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2011 | 10 | 0.030 |
Why?
|
| Immunization, Secondary | 1 | 2011 | 17 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2015 | 1173 | 0.020 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2010 | 23 | 0.020 |
Why?
|
| Indomethacin | 1 | 2010 | 107 | 0.020 |
Why?
|
| Vaccination | 1 | 2011 | 182 | 0.020 |
Why?
|
| Lipid Peroxides | 1 | 2009 | 19 | 0.020 |
Why?
|
| Glutathione Disulfide | 1 | 2009 | 31 | 0.020 |
Why?
|
| Catalase | 1 | 2009 | 85 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2009 | 289 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 648 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 1341 | 0.020 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 1 | 2007 | 41 | 0.020 |
Why?
|
| Pulmonary Surfactant-Associated Protein C | 1 | 2007 | 11 | 0.020 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2007 | 20 | 0.020 |
Why?
|
| Vena Cava, Inferior | 1 | 2007 | 41 | 0.020 |
Why?
|
| Acetylcholine | 1 | 2007 | 64 | 0.020 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2007 | 17 | 0.020 |
Why?
|
| Pancreatic Elastase | 1 | 2007 | 33 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2007 | 32 | 0.020 |
Why?
|
| Respiration | 1 | 2007 | 91 | 0.020 |
Why?
|
| Ductus Arteriosus | 1 | 2006 | 13 | 0.020 |
Why?
|
| Serine | 1 | 2007 | 99 | 0.020 |
Why?
|
| Nitroarginine | 1 | 2006 | 2 | 0.020 |
Why?
|
| Parturition | 1 | 2006 | 15 | 0.020 |
Why?
|
| Penicillamine | 1 | 2005 | 10 | 0.020 |
Why?
|
| Calcimycin | 1 | 2005 | 32 | 0.020 |
Why?
|
| Reference Values | 1 | 2007 | 579 | 0.020 |
Why?
|
| Nitric Oxide Synthase | 1 | 2006 | 163 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2007 | 331 | 0.020 |
Why?
|
| Parathyroid Hormone-Related Protein | 1 | 2002 | 15 | 0.010 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2002 | 32 | 0.010 |
Why?
|
| Species Specificity | 1 | 2002 | 302 | 0.010 |
Why?
|
| Cell Count | 1 | 1995 | 248 | 0.010 |
Why?
|